RELATIONSHIP OF BODY IRON STATUS AND SERUM ALUMINUM IN CHRONIC RENAL-INSUFFICIENCY PATIENTS NOT TAKING ANY ALUMINUM-CONTAINING DRUGS

The present study examines the serum aluminum (Al) and daily urine Al excretion in 50 patients with chronic renal insufficiency (CRI) who ar e not taking any Al-containing agents. The influence of body iron stor es and hematological indexes on the above parameters were also studied . Data on a group of 20 healthy subjects not taking any drugs were inc luded for comparisons. The basal Al levels in CRI patients (10.5+/-9.7 mu g/l) were significantly higher than those (3.8+/-2.4 mu g/l) of th e normal subjects. In addition, the renal Al clearance (2.98+/-0.35 ml /min) in CRI patients was significantly lower than that(4.93+/-0.21 ml /min) in normal subjects. Although all serum Al levels of our patients were within the nontoxic range (<50 mu g/l), the results of our study showed a negative correlation between serum Al and serum transferrin saturation (r=-0.40, p<0.005) as well as serum iron (r=-0.406, p<0.005 ). There was a negative correlation between daily urine Al excretion a nd serum ferritin levels (r=-0.305, p = 0.031). The study group is fur ther divided into 2 subgroups, i.e, group A (ferritin <100 mu g/l) and group B (ferritin >300 mu g/l). The daily urine Al excretion in group A was higher than that in group B. In conclusion, our study first dem onstrates that Al tends to be accumulated in patients with CRI, simila r to Al in patients with hemodialysis, and the chronic low-level Al ex posure in CRI patients may affect body iron status and metabolism, or iron status may play a role in Al absorption and excretion. We further suggest that all potential Al exposure sources, especially Al-contain ing drugs, contaminations of diets and citrates in food, must be avoid ed as much as possible to minimize the risk of Al toxicity in CRI pati ents. The possible long-term clinical significance of these findings r emains to be determined.